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Kabuki syndrome (also called Niikawa-Kuroki syndrome) is a rare genetic disease described for the first time in Japan,
characterised by anomalies in multiple organ systems and often associated with autoimmune disorders and impaired
immune response. We herein report the clinical history, the therapeutic approach and the outcome of two children
with Kabuki syndrome who developed autoimmune haematological disorders (haemolytic anaemia and immune
thrombocytopenia). Factors regarding differential diagnosis and interventions in better management of this syndrome
and its complications are discussed. This is the first report of Italian children with autoimmune haematological disorders
complicating Kabuki syndrome.
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The condition named Kabuki make-up syndrome (KS) is a
rare multiple anomaly syndrome. The name was attributed
because of the facial resemblance to the make-up used in
traditional Japanese Kabuki theatre. It was first described
in 1981 by Niikawa [1] and Kuroki [2,3]. The estimated
prevalence of KS in Japan was 1/32,000 people with almost
equal sex distribution. Although it was initially considered
as a disease affecting exclusively the Japanese population,
several reports support a widespread ethnic distribution of
KS [4]. The main clinical characteristics are distinctive facial
features: elongated palpebral fissures with eversion of the
lateral third of the lower eyelid; arched and broad eyebrows;
short columella with depressed nasal tip; large, prominent,
or cupped ears. Other findings may include: minor skeletal
anomalies, persistence of fetal fingertip pads, from mild to
moderate intellectual disability, postnatal growth deficiency,
congenital heart defects, genitourinary anomalies, cleft
lip and/or palate, gastrointestinal anomalies. Functional
differences can include:seizures, endocrinologic abnor-
malities (premature thelarche in females, feeding prob-
lems, hearing loss), hypogammaglobulinemia, increased* Correspondence: paola.giordano@uniba.it
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reproduction in any medium, provided the orsusceptibility to infections and autoimmune disorders as
idiopathic thrombocytopenic purpura (ITP), haemolytic
anemia, thyroiditis and vitiligo [5,6]. The prevalence of
major findings is summarised in the table (Table 1) [7-12].
Genetic basis of KS has been recently elucidated. Mutations
in the mixed lineage leukaemia 2 gene, KMT2D (formerly
MLL2) mapping on chromosome 12q13.12, are described
in 55-80% of KS patients [13]. KMT2D is a histone H3
lysine 4 (H3K4)-specific methyl transferase that belongs
to the SET1 family of human SET-domain protein methyl-
transferase superfamily. KMT2D acts as a part of multipro-
tein complex named ASCOM. It interacts with oestrogen
receptor-α and it is important for epigenetic transcriptional
activation and for embryonic development [14]. KMT2D
has emerged as one of the most frequently mutated genes
in a variety of cancers, including lymphoma, medulloblas-
toma and gastric cancer, thus supporting a role as a tumor
suppressor in various tissues [15]. In patients without
KMT2D mutation, KDM6A gene mutations have been
reported. Lederer and Miyake described, respectively,
deletion and point mutations as cause of KS [16,17].
KDM6A located at Xp11.3 encodes the lysine demethylase
6A demethylating di-and trimethyl-lysine 27 on histone
H3. Like KMT2D, KDM6A plays an important role in
embryogenesis and development [18]. In a recent multicen-
ter study short stature and postnatal growth retardational Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 The prevalence of major findings in more than
350 individuals with Kabuki syndrome (KS)
Finding Prevalence (%)
Typical facial features* ~ 95
Intellectual disability 92
Hypotonia 25-89
Postnatal growth retardation 35-81
Joint hypermobility 50-75
Feeding difficulties 70





Cleft lip and/or palate 33
Renal and urinary tract anomalies 25
Immune dysfunction: ~ 20
Hypogammaglobulinemia,




*Elongated palpebral fissures with eversion of the lateral third of the lower
eyelid; Arched and broad eyebrows; Short columella with depressed nasal tip;
and large, Prominent, or cupped ears.
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but in only half of the group with KMT2D mutations [19].
As KS is a multisystemic disorder, people with KS may
require various diagnostic and screening tests, assessments,
referrals and multidisciplinary interventions at different
stages of their lives [9-12]. For these reasons in 2011,
the panel of DYSCERNE team (a network of centres of
expertise for dysmorphology), funded by the European
Commission Public Health Executive Agency, wrote the
“Kabuki Syndrome Clinical Management Guidelines” [20].
These guidelines have been developed using a robust
methodology based on the one used by the Scottish Inter-
collegiate Guidelines Network (SIGN). The method has
been adapted to suit rare conditions where the evidence
base is limited, and where expert consensus plays a greater
role. Of note in the natural history of the KS, an abnormal
immune regulation may occur. Some authors reported their
experiences in the treatment of KS patients with im-
munodeficiencies [21] or autoimmune disorders [22]. In
this paper, we contribute to the list describing two Italian
KS children with autoimmune haematological disorders
and their clinical management.
Case 1
This female patient was diagnosed as KS when she was
ten years old through genetic counselling. Her typicalfacial features were: large and low set ears, elongated
palpebral fissures with eversion of the lateral third of
the lower eyelid. Additional phenotypic malformations
were: brachydactyly V, prominent fingertip pads, muscle
hypotonia, joint hyperlaxity, gastroesophageal reflux, left
convex scoliosis, moderate mitral stenosis. She was born
preterm at 34th weeks of gestational age by caesarean
section. In the perinatal period she presented halting
weight gain. At the age of three months it was detected a
ventricular septal defect (VSD) and a mild aortic coartation,
surgically corrected. During her first year of life,a delay of
psychomotor development arose. She faced a new heart
surgery when she was three years old for aortic decoarta-
tion. Screening of KMT2D gene (by PCR amplification
of all the 54 exons spanning the KMT2D gene and then
by high-throughput sequencing confirming with direct
sequencing) [23] didn’t find any mutations, otherwise
mutation analysis of KDM6A gene has not yet been per-
formed. She was referred to our paediatric haematology
unit at the age of eleven for relapsing of chronic immune
thrombocytopenia, onset two years earlier and treated with
courses of intravenous immunoglobulin and steroid. At this
time laboratory investigations revealed: immune haemolytic
anaemia (Hb 8.7 g/dl, direct and indirect Coombs test posi-
tive), thrombocytopenia (platelet count 4000/mm [3]) and
partial defect of serum IgA levels (26 mg/dl). She received
intravenous immunoglobulin at the dose of 0.8 g/Kg for
two days in association with metil-prednisolone at the dose
10 mg/Kg i.v for three days. After tapering steroid therapy,
she was discharged with partial haematological remission,
(Hb 12.8 g/dl, Coombs test positive, Plt 13600/mm [3]) and
started at home treatment with low dose of prednisone
(2 mg/Kg/day). In the following years the patient experi-
enced relapsing course of the autoimmune cytopenia which
needed to change immunosuppressive therapy with cyclo-
sporine achieving a sustained haematological remission.
Nowadays the patient has a resolution of her thrombo-
cytopenia but remains Coombs positive.
Case 2
This male patient presented hypodontia, lower lip pits,
long palpebral fissures, prominent eyelashes, thinning of
the central part of the eyebrow, mildly protuberant ears,
prominent fingertip pads and hypospadias (Figures 1 and 2).
He underwent surgery to correct palatoschisis and ven-
tricular septal defect, at eight and eighteen months of age,
respectively. At the age of nine he was admitted to our
paediatric haematology unit for leukopenia and thrombo-
cytopenia: his platelet count was 16000/mm3, and white
blood cell count 1400/mm3. Serology for viral and micro-
biological infections was negative. Laboratory investigations
revealed normal immunoglobulin levels and positive direct
Coombs test. Bone marrow needle aspirate showed nor-
mocellular marrow and an increased number of immature
Figure 1 Typical facial features (front shot).
Figure 2 Typical facial features (profile shot).
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escence in situ hybridization assay on bone marrow sample
displayed no cytogenetic abnormalities in 7, 8, 21 chro-
mosomes. To evaluate malformation framework, a high-
throughput sequencing of KMT2D gene [23] was performed.
The analysis showed a c.16384 G>C heterozygosis sequence
variation resulting in the change of aspartic acid with
histidine and causing the D5462H mutation. During hos-
pitalisation, the patient received a single intravenous
immunoglobulin administration, at the dose of 0.8 g/Kg,
achieving a partial response of platelet count (98000/mm3).
He was discharged with steroid home therapy (oral pred-
nisone, 2 mg/Kg/day and progressive dose reduction in one
month). During follow-up, he had a chronic and relapsing
course of the autoimmune cytopenia, reason for which the
study of lymphocyte apoptosis was carried out. Lymphocyte
survival after Fas stimulation resulted normal and also the
ratio of double negative (DN) [CD3+ TCRαβ +CD4-CD8-]
T cells was within normal values (1%), thus ruling out an
autoimmune lymphoproliferative syndrome (ALPS). Cur-
rently, three years after the first observation, the patient
still has persistent leukopenia and relapsing episodes of
thrombocytopenia, treated with recurrent courses of intra-
venous immunoglobulin and steroid.
Discussion
KS is a multiple anomaly/mental retardation syndrome.
In 2010, KMT2D was identified as the first causative gene
of KS. On the basis of published reports, 55-80% of KS
cases can be explained by mutations in these gene. Re-
cently, also KDM6A deletions and point mutations have
been detected in KS patients, however in 20 - 45% of cases
the genetic basis remains unknown. Therefore different
authors emphasises the search of additional KS causative
genes [24]. This syndrome is sometimes associated with
autoimmune abnormalities, such as idiopathic thrombocy-
topenic purpura (ITP) (from 1.6 to 17% of cases) [9], auto-
immune haemolytic anaemia, leukoplakia, vitiligo and
thyroiditis. Since the autoimmune disease does not occur
until later childhood, and many of KS reports regard the
paediatric age, the real frequency of autoimmune condi-
tions in this syndrome might be underestimated. Moreover,
KS patients have increased susceptibility to infection due
to immune defects, particularly hypogammaglobulinemia
[21]. Of note, the combination of immune deficiency and
increased incidence of autoimmune disease has also been
observed in patients with DiGeorge Syndrome (DGS) and
Common Variable Immune Deficiency (CVID) [25-33].
The DGS is most commonly associated with chromosome
22q11.2 deletion and includes cardiac malformations and
facial abnormalities, as well as KS, but also hypoparathyr-
oidsm and T-cell deficiency [34]. On the other hand, the
pattern of antibody abnormalities seen in children with KS
resembles Common Variable Immune Deficiency (CVID).
Giordano et al. Italian Journal of Pediatrics 2014, 40:10 Page 4 of 5
http://www.ijponline.net/content/40/1/10CVID is an heterogeneous immune disorder characterised
by failure to properly induce B cell development and an
increased incidence of autoimmune disease. Haemato-
logical disorders complicating KS have already been de-
scribed [10,35], but to our knowledge, our cases are the
first occurring in paediatric age in Italy. Diagnosis of
Kabuki was made on the basis of facial features, confirmed
in one case by mutation analysis of KMT2D gene. Since
the high prevalence of autoimmune lymphoproliferative
syndrome in children with idiopathic autoimmune cytope-
nias, [36], one out of two patients who had a partial defect
of IgA, underwent the study of FAS-mediated apoptosis
and the detection of DN lymphocytes. ALPS is a genetic
disorder of FAS apoptotic pathway causing autoimmune
cytopenia, organomegaly, lymphadenopathy and increased
risk of malignancy. Interestingly, the autoimmune cytope-
nia associated with KS is often chronic. The conventional
therapy (intravenous immunoglobulins and steroids) of this
condition is often marked by lack of response and relapse
of autoimmunity and/or therapy side effects. In particular,
Torii et al. [35] showed the successful treatment with
Rituximab of refractory idiopathic thrombocytopenic pur-
pura. We treated our cases according the recommendations
of Paediatric Oncology and Haematology Italian Associ-
ation [37] keeping in mind the risk for these patients to
develop hypogammaglobulinema [21]. The use of different
immunosuppressive protocols, chosen on the experience
of each single centre, should lead medical community to
standardise therapeutic approaches for KS. Collecting data,
concerning a considerable number of patients, about
diagnosis, clinical, therapy and outcome might help to
improve the management of KS patients as the French
registry demonstrates [38]. In addition, due to the under-
lying immune dysregulation, we suggest to perform a
immunologic evaluation at the time of diagnosis, in order
to reduce preventable morbidity in these patients.
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